{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Miller KE"],"funding":["NCI","NCRR NIH HHS","Nationwide Insurance Innovation Fund","NCI NIH HHS","NIH"],"pagination":["498-506"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8846434"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["28(3)"],"pubmed_abstract":["<h4>Purpose</h4>Previously, clinical trials of experimental virotherapy for recurrent glioblastoma multiforme (GBM) demonstrated that inoculation with a conditionally replication-competent Δγ<sub>1</sub>34.5 oncolytic herpes simplex virus (oHSV), G207, was safe. Following the initial safety study, a phase Ib trial enrolled 6 adult patients diagnosed with GBM recurrence from which tumor tissue was banked for future studies.<h4>Patients and methods</h4>Here, we analyzed tumor RNA sequencing (RNA-seq) data obtained from pre- and posttreatment (collected 2 or 5 days after G207 injection) biopsies from the phase Ib study patients.<h4>Results</h4>Using a Spearman rank-order correlation analysis, we identified approximately 500 genes whose expression pattern correlated with survival duration. Man"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study."],"pmcid":["PMC8846434"],"funding_grant_id":["P01 CA071933","R01 CA217179","U54 CA232561","R01-CA217179","U54-CA232561","R01 CA222903","R01-CA222903","M01 RR000032"],"pubmed_authors":["Cassady KA","Miller AR","Prasad N","Leavenworth JW","Clements J","Miller KE","Aban IB","Gillespie GY","Roth JC","Mardis ER","Markert JM","Schieffer KM","Whitley RJ","Leraas K"],"additional_accession":[]},"is_claimable":false,"name":"Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study.","description":"<h4>Purpose</h4>Previously, clinical trials of experimental virotherapy for recurrent glioblastoma multiforme (GBM) demonstrated that inoculation with a conditionally replication-competent Δγ<sub>1</sub>34.5 oncolytic herpes simplex virus (oHSV), G207, was safe. Following the initial safety study, a phase Ib trial enrolled 6 adult patients diagnosed with GBM recurrence from which tumor tissue was banked for future studies.<h4>Patients and methods</h4>Here, we analyzed tumor RNA sequencing (RNA-seq) data obtained from pre- and posttreatment (collected 2 or 5 days after G207 injection) biopsies from the phase Ib study patients.<h4>Results</h4>Using a Spearman rank-order correlation analysis, we identified approximately 500 genes whose expression pattern correlated with survival duration. Man","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2026-05-31T02:35:36.01Z","creation":"2025-04-07T04:06:24.381Z"},"accession":"S-EPMC8846434","cross_references":{"pubmed":["35105718"],"doi":["10.1158/1078-0432.CCR-21-2636"]}}